What is Fertility Serum for IVD Development?

Which fertility hormones are measured by IVD assays?

Fertility and reproductive endocrinology IVDs cover a broad range of hormones with distinct clinical applications:

Hormone / Analyte	Clinical use	Key decision levels
β-hCG (human chorionic gonadotropin)	Pregnancy detection, ectopic pregnancy, molar pregnancy monitoring	<5 IU/L (negative), >25 IU/L (positive), >100,000 IU/L (1st trimester peak)
AMH (Anti-Müllerian Hormone)	Ovarian reserve assessment, IVF prognosis, PCOS	<0.5 ng/mL (low), 1–4 ng/mL (normal), >5 ng/mL (high/PCOS)
FSH (Follicle Stimulating Hormone)	Ovarian reserve, menopause, pituitary function	>10 IU/L (reduced reserve), >25 IU/L (menopause)
LH (Luteinising Hormone)	Ovulation detection, LH surge monitoring	LH surge 2–3× baseline — ovulation typically 24–36h after surge
Progesterone	Ovulation confirmation, luteal phase assessment, early pregnancy support	>3 ng/mL (ovulation confirmed), >10 ng/mL (adequate luteal phase)
Estradiol (E2)	Follicular monitoring, IVF stimulation, menopause	Follicular: 20–150 pg/mL; pre-ovulatory: >200 pg/mL

Why is native human serum the correct matrix for fertility IVD development?

Fertility hormone assays are highly matrix-sensitive — the protein composition, viscosity, and endogenous interference burden of the sample matrix significantly affect assay performance. Native human serum from pregnant or hormone-defined donors provides the most clinically relevant matrix for calibrator preparation, commutability assessment, and cross-reactivity testing. Spiked or recombinant hormone preparations in artificial buffers behave differently from native hormone in a complex protein matrix — particularly for assays measuring structurally complex glycoprotein hormones such as hCG, FSH and LH, where glycoform distribution affects immunoreactivity.

hCG assay development — why serum AND urine are needed

Pregnancy tests are designed for two primary matrices: serum (laboratory quantitative hCG) and urine (home pregnancy tests and point-of-care qualitative assays). The same hCG molecule behaves differently in these two matrices — urinary hCG is partially metabolised and predominantly present as hCG beta core fragment, while serum hCG is predominantly intact hCG and nicked hCG. IVD manufacturers developing urine pregnancy tests must validate with native urine from pregnant donors — not serum. For quantitative serum hCG assays, trimester-specific native serum across the full concentration range is required for calibration and commutability assessment.

Hook effect in hCG assays

At very high hCG concentrations (typically >500,000 IU/L, seen in molar pregnancy and choriocarcinoma), some immunoassay formats show a hook effect — the signal paradoxically decreases at very high analyte concentrations because both capture and detection antibodies are saturated with free analyte rather than forming the sandwich complex. Characterising the hook effect requires native serum from very high hCG donors or serial dilutions of early pregnancy serum at high concentrations. This is a mandatory part of performance evaluation for quantitative hCG IVDs.

Key Facts

• Pregnancy serum is typically collected as native Serum OTC (off-the-clot) to maximise protein content and avoid anticoagulant interference — the most physiologically representative matrix for IVD calibration
• Trimester-specific pools are produced from donors within defined gestational week ranges: 1st trimester (weeks 1–12), 2nd trimester (weeks 13–24), 3rd trimester (from week 25)
• hCG (human chorionic gonadotropin) rises from <5 IU/L in non-pregnant women to >100,000 IU/L in the first trimester — IVD assay calibration requires samples across this full dynamic range
• AMH (Anti-Müllerian Hormone) is the primary biomarker for ovarian reserve — ranges from <0.5 ng/mL (diminished reserve) to >5 ng/mL (high reserve / PCOS risk)
• FSH rises significantly in perimenopause and menopause — FSH-positive serum at defined levels is required for menopause panel assay development
• Preeclampsia serum (confirmed diagnosis) is used for sFlt-1/PlGF ratio assay development — the key biomarker for preeclampsia risk assessment
• Consecutive donations from the same donor allow longitudinal studies tracking hormone changes across trimesters or ovulation cycles in the same matrix
• SeamlessBio supplies trimester-specific single donations (1–10 mL) and 100 mL pools, plus single-donation fertility hormone samples across 8 analytes

Further Reading

• Fertility & Pregnancy Serum Materials
• What is Human AB Male Serum?
• Disease State Serum Panels
• What is Disease State Serum?
• Human Biomaterials & IVD — Overview

SeamlessBio GmbH · Passau, Germany · info@seamlessbio.de · +49 851 37932226